RESEARCH DOSSIER
Psychotropic Drug Targets and Pharmacodynamics
Abstract. Psychotropic pharmacodynamics concerns how compounds interact with neural receptors, transporters, and signaling pathways and how those interactions can influence psychological and clinical outcomes. This fundamental monograph reviews receptor theory, binding and operational models, efficacy and potency, agonism and antagonism, allostery, biased signaling, molecular imaging, transmitter transport, and the mechanisms of psychotropic drug classes. Its historical reconstruction runs from allosteric and operational receptor theories through human PET target-engagement studies. Primary evidence includes dopamine D2 occupancy studies of antipsychotic response, serotonin transporter imaging of SSRIs, laboratory identification of dopamine partial agonism and κ-opioid agonism, and controlled clinical investigations of NMDA-antagonist treatment effects. The work evaluates biochemical assays, functional signaling, electrophysiology, occupancy imaging, behavioral tasks, clinical endpoints, replication, adaptation, and causal inference. Its synthesis identifies target engagement as a crucial intermediate variable whose relation to symptom change remains conditional on circuitry, exposure, timescale, and measurement. Open research problems include target-to-behavior mediation, polypharmacology, individual variation, functional bias, and longitudinal adaptation. This is an evidence-based critical narrative research synthesis, not a registered systematic review, a meta-analysis, new clinical trial, or an individual treatment guide.
Keywords: psychotropic drug targets; psychopharmacodynamics; receptor occupancy; receptor affinity; intrinsic efficacy; partial agonism; antagonism; allosteric modulation; biased agonism; functional selectivity; serotonin transporter; dopamine D2 receptor; GABA-A receptors; NMDA receptor; PET neuroimaging; dose–response; psychiatric pharmacology; mechanistic inference; psychopharmacology; Artificial Era
Introduction: The Pharmacodynamic Problem in Psychotropic Science
Psychotropic drug pharmacodynamics concerns the interactions through which a chemical agent changes signaling in nervous-system cells and, under specified biological and behavioral conditions, produces measurable changes in cognition, affect, perception, arousal, motivation, or action. The relevant research object is a causal sequence rather than a drug label: chemical concentration at a target, binding or other target engagement, alterations in molecular activity, changes within cells and circuits, and consequences measured in organisms. Each transition requires independent evidence. A compound may bind a receptor at nanomolar concentrations yet produce no corresponding behavioral response at the exposure, location, or time studied. A clinical effect may also arise through several targets or through adaptation well after the initiating interaction. The monograph systematically examines these levels and the inferential limits between them. Black & Leff (1983) Hyman & Nestler (1996)
The research scope includes receptor affinity and efficacy, full and partial agonism, antagonism, allostery, biased signaling, neuronal transporter inhibition, ion-channel modulation, binding kinetics, receptor occupancy, concentration–response analysis, and mechanisms connecting pharmacological initiation to clinical or behavioral effects. Antipsychotics, antidepressants, anxiolytics, sedative agents, psychedelics, and selected experimental compounds serve as mechanistic examples; their therapeutic dosing, prescribing, pharmacokinetic disposition, and pharmacogenomic interpretation belong to neighboring dossiers. The intellectual question is how evidence from purified targets and living cells can be combined with human molecular imaging, electrophysiology, controlled trials, and behavior without confusing one level with another. Kenakin (2011) Kapur et al. (2000)
This work is a critical narrative synthesis of primary pharmacology, occupancy imaging, and clinical experiments, supplemented by methodological and mechanistic reviews. It reports no new experiment, participant-level analysis, registered search protocol, meta-analysis, or individual clinical recommendation. The evidential approach privileges studies that specify assay systems, exposure conditions, receptor or transporter subtypes, comparators, uncertainty, and direct outcomes. Reported numerical thresholds are treated as findings from particular study designs and populations, not universal molecular laws. Across the examples surveyed, target engagement is an experimentally important intermediate measurement, while therapeutic or psychological causation requires convergent functional and organism-level evidence. Farde et al. (1988) Meyer et al. (2004)
Scientific Definitions and Levels of Explanation
An endogenous ligand is a naturally present molecule that binds a target; an exogenous ligand can bind the same or a different site. A receptor is a macromolecular system whose conformational and signaling states can be altered by ligand interaction. An ion channel regulates membrane conductance, and a transporter moves substrates across a membrane through a defined molecular cycle. Affinity describes a binding relationship under specified conditions; potency refers to a concentration associated with a defined measured effect; efficacy concerns a ligand's capacity to activate an output in an assay system. These constructs answer different questions. A drug may have high affinity yet low intrinsic efficacy, while a potent observable effect may reflect signaling amplification or a high target density rather than unusually tight binding. Black & Leff (1983) Burris et al. (2002)
Target engagement means that a compound interacts with an intended molecular component in a relevant biological context. Occupancy is the fraction of accessible targets bound by a ligand or inferred from displacement of a radiotracer; functional engagement requires evidence that the target's activity or downstream signaling changes. Mechanistic mediation is a stronger claim: altering the proposed target should systematically alter the drug-induced effect, with plausible control of alternative explanations. Causal attribution therefore advances through separate stages: biochemical binding, cellular response, tissue or brain engagement, physiological change, behavioral change, and validated effects on a clinical outcome. Every stage can be studied rigorously while leaving the next stage uncertain. Farde et al. (1988) Kapur et al. (2000)
Psychotropic drugs often have several pharmacologically active molecular interactions. A list of affinity constants can prioritize mechanisms, but its ranking depends on receptor expression, free exposure, binding kinetics, endogenous competitors, active metabolites, and assay context. The expression 'mechanism of action' should therefore name a supported causal pathway at a specified level, such as serotonin transporter inhibition in an occupancy study, rather than imply that one measured binding event explains an entire psychiatric diagnosis. The same discipline is required in comparing rodent behavior, human neuroimaging, and clinical rating scales: their observable endpoints differ and need bridges of measurement and causal inference. Rothman & Baumann (2003) Meyer et al. (2004)
Historical Foundations of Receptor Theory and Experimental Pharmacology
Classical receptor reasoning emerged from the quantitative relation between drug concentration and biological response, and matured through competing accounts of occupancy and stimulus generation. The central historical development was the recognition that the proportion of occupied binding sites need not equal the proportion of maximal physiological effect. Black and Leff's 1983 operational model integrated concentration–effect curves with a formal relationship between the ligand–receptor interaction and tissue response, making differences in system sensitivity analytically explicit. Their framework helped explain why a compound can appear stronger in one tissue than another even when the underlying molecular affinity is unchanged. Black & Leff (1983)
Allosteric theory provided another influential historical trajectory. Monod, Wyman, and Changeux proposed a model of transitions among conformational states of proteins in 1965, establishing a conceptual foundation that later became relevant to ligand-gated receptors and other regulatory proteins. Its importance lies in treating receptor function as a distribution of states whose stabilization changes observable activity. Subsequent structural and functional work has shown that real receptor systems may be more complex than a small-state model, but the principle of conformational regulation remains central to contemporary pharmacodynamics. The historical model is a starting point for experimentally testable mechanisms, not a claim that every psychotropic receptor follows the same transition scheme. Monod et al. (1965) Changeux (2012)
By the late twentieth century, positron emission tomography made receptor occupancy measurable in living human brains. Farde and colleagues' 1988 study used carbon-11-labeled raclopride to investigate striatal dopamine D2 occupancy in patients receiving antipsychotic medications. This moved molecular pharmacology from binding assays toward a direct estimate of target engagement in the treated organism. Later controlled imaging studies connected such occupancy measurements to clinical outcomes and side effects, permitting evaluation of pharmacodynamic windows under observed treatment conditions. The historical progression moved from receptor theory to biochemical methods, functional assays, and in-vivo imaging, with each method preserving distinct assumptions. Farde et al. (1988) Kapur et al. (2000)
Ligand Binding, Affinity, Selectivity, and Receptor Availability
At equilibrium and for a single class of noninteracting binding sites, fractional occupancy can be represented by the free ligand concentration divided by the sum of that concentration and its equilibrium dissociation constant. The relation is instructive because the same nominal administered amount can yield different occupancy when free concentrations differ. It does not by itself describe effects under heterogeneous receptor populations, cooperativity, competition, rapid endogenous neurotransmission, variable tissue access, or significant kinetic disequilibrium. Experimenters must disclose whether concentrations refer to total drug, unbound extracellular drug, or another analytical compartment before mapping a binding estimate to a neural effect. Black & Leff (1983) Farde et al. (1988)
Affinity is measured using saturation or competition assays, each with assumptions about labeled tracers, reference ligands, receptor states, nonspecific binding, and equilibrium. Inhibitory concentration values from displacement experiments are not automatically dissociation constants; their interpretation depends on tracer concentration, binding conditions, and the model used. A ligand reported as selective in one panel may interact with additional targets as exposure rises. The most informative profiles therefore report the panel studied, the assay system, the concentrations tested, and limitations of detection. The salvinorin A studies illustrate the explanatory gain when a compound's pharmacological profile is tested across a broad receptor and transporter panel and its activity is then established functionally at the identified target. Roth et al. (2002) Chavkin et al. (2004)
Receptor availability changes with endogenous transmitter release, trafficking, receptor regulation, brain region, cellular state, and disease-associated physiology. A radiotracer displacement measure can reflect occupancy by an administered drug, but interpretation may be complicated by changes in transmitter competition or receptor accessibility. Selectivity also has anatomical dimensions: different neuronal populations may express distinct isoforms or signaling partners, producing distinct outcomes under the same circulating exposure. The pharmacodynamic identity of a psychotropic compound is therefore a joint property of molecular interactions and the biological system in which they occur. Olsen & Sieghart (2008) Farde et al. (1988)
Potency, Efficacy, Receptor Reserve, and Concentration–Response Curves
A concentration–response curve translates graded exposure into a defined observable response. EC50 names the concentration associated with half of the fitted maximal effect in that assay; Emax names its asymptotic response scale. Neither is automatically a measure of receptor affinity, and both can depend on cell type, receptor expression, time of measurement, downstream amplification, and endpoint selection. The difference is clearest in signaling systems with spare receptors, where a relatively low proportion of occupied receptors can elicit a large response. Operational pharmacology formalizes this distinction by including properties of ligand efficacy and the responding system. Black & Leff (1983) Black et al. (1985)
The slope and shape of a concentration–response relation carry mechanistic information but require appropriate caution. Saturation may reflect exhaustion of accessible receptors, downstream limitations, assay ceiling effects, cytotoxicity, or competing pathways. Apparent biphasic responses can arise from receptor heterogeneity or engagement of another target at greater exposure. When a behavioral outcome is reported at only one dose, the full concentration–effect relation remains unknown; a single significant result provides neither a pharmacodynamic threshold nor a demonstration of optimality. At the organismal level, dosing also changes exposure, so mechanistic interpretation often requires a measured drug concentration alongside the response. Black et al. (1985) Hyman & Nestler (1996)
Pharmacological comparisons should distinguish potency shifts from changes in maximal attainable response. An antagonist may shift an agonist curve without changing its maximum under certain competitive equilibrium conditions; other modes of antagonism or system limitations can reduce maximal response. Receptor reserve and nonlinear downstream coupling complicate simple inferences from either pattern. Causal interpretation improves when concentration–response studies are repeated across more than one functional assay, and when predicted patterns are compared against target-specific perturbations and, where possible, quantitative binding measurements. Black & Leff (1983) Kenakin (2011)
Full Agonism, Partial Agonism, Inverse Agonism, and Antagonism
An agonist increases a specified receptor-dependent response, while a partial agonist produces a lower maximal effect than a reference full agonist under defined experimental conditions. These classifications are relational and assay-specific, because receptor density and coupling can alter what counts as maximal response. A partial agonist can compete with a stronger agonist for binding and reduce signaling in a setting where endogenous stimulation is high, while retaining positive activity in settings with little endogenous stimulation. This dual possibility makes pharmacodynamic inference depend on the amount of endogenous ligand and the state of the signaling network. Black & Leff (1983) Burris et al. (2002)
Burris and colleagues' 2002 investigation characterized aripiprazole as a high-affinity partial agonist at human dopamine D2 receptors. The study supplied a molecular and functional framework for interpreting a compound whose behavior differs from a pure antagonist in selected experimental systems. Nevertheless, the term partial agonist does not imply that one drug automatically 'normalizes' dopamine throughout the brain. Distinct signaling pathways, receptor populations, presynaptic actions, and regional responses remain separate research questions. The clinical usefulness and adverse-event profile of a compound must be established through appropriately designed human studies, rather than inferred only from its classification in recombinant cells. Burris et al. (2002) Kenakin (2011)
An antagonist reduces the action of an agonist through a defined interaction; neutral antagonism is distinguished conceptually from inverse agonism, which reduces constitutive receptor signaling when such signaling exists. Demonstrating inverse agonism requires evidence of basal activity and its reduction, with careful control for assay baseline and system drift. Competitive, allosteric, and insurmountable inhibition are experimentally distinguishable only under adequate binding and functional conditions. Classification should be restricted to the exact receptor state, endpoint, and experimental system measured; a compound may display antagonism at one pathway while promoting another. Kenakin (2011) Black et al. (1985)
Allosteric Modulation and Receptor Conformational States
Allosteric modulation occurs when a ligand binds at a site distinct from the principal orthosteric signaling site and alters receptor binding, gating, coupling, or another function. A positive allosteric modulator can amplify the response to an endogenous ligand, and a negative modulator can reduce it; some ligands also possess intrinsic activity. This architecture permits dependence on the timing and location of native neurotransmitter release. The experimental distinction between modulating endogenous activity and directly activating a receptor is fundamental when relating molecular mechanisms to time-varying network behavior. Monod et al. (1965) Changeux (2012)
GABA-A receptors illustrate the importance of subunit organization. Their pentameric ion-channel structures produce pharmacological diversity, with synaptic and extrasynaptic populations supporting different temporal patterns of inhibition. Sigel and Steinmann summarized how benzodiazepines and other modulators act on these receptors, while Olsen and Sieghart distinguished experimentally supported native receptor subtypes. An observed change in chloride conductance does not specify a unique experience of calmness, amnesia, sleepiness, or impaired coordination: those outcomes require anatomically distributed neural and behavioral evidence. Sigel & Steinmann (2012) Olsen & Sieghart (2008)
Allosteric models create useful design opportunities because different compounds can alter sensitivity to endogenous transmitter while preserving other components of receptor function. Their selectivity, however, may depend on subunit makeup and tissue context, and an apparent plateau can reflect either receptor-level constraints or downstream assay behavior. Structural evidence can identify candidate binding sites; electrophysiological and biochemical studies are needed to establish how binding modifies function. Behavioral experiments then test whether the predicted modulation contributes to a defined outcome. Treating these as sequential experimental questions preserves the explanatory value of molecular discoveries without overstating their reach. Changeux (2012) Sigel & Steinmann (2012)
Biased Agonism and Functional Selectivity
Classical binary labels are insufficient for receptors that signal through several coupled pathways. A ligand may preferentially engage one G-protein family, arrestin-dependent processes, or other signaling partners, and the observed ranking of ligand efficacy can change when the assay endpoint changes. Kenakin's analysis of biased receptor signaling characterized this multidimensional problem: different ligands may stabilize receptor conformations associated with different relative signaling outcomes. Testing one intracellular reporter and calling the result the receptor's universal efficacy obscures other pharmacologically relevant activities. Kenakin (2011)
Quantifying bias requires explicit selection of reference ligands, signaling endpoints, and a model connecting concentrations to transduction. Functional selectivity can reflect ligand-specific interactions, receptor density, pathway amplification, kinetic differences, and experimental conditions. Comparisons across heterogeneous cell lines may exaggerate apparent ligand differences because cells express distinct transduction machinery. Kenakin and colleagues' 2012 quantitative method illustrates efforts to compare functional selectivity rather than relying on categorical descriptions. Such comparisons remain conditional on model assumptions and the measured pathways. Kenakin et al. (2012)
In psychotropic pharmacology, biased signaling is a plausible route by which molecularly similar drugs might differ in neural action. The explanatory opportunity is substantial, but demonstration of receptor bias in an expression system does not establish improved psychiatric outcomes, reduced adverse effects, or a particular psychological experience. A compelling translational chain would demonstrate selective signaling under realistic exposure, reproduce it in relevant neural preparations, modify it with target-specific interventions, and connect the alteration to controlled behavioral or clinical endpoints. The same requirements apply when discussing dopamine partial agonists and serotonin receptor-active compounds. Kenakin (2011) Burris et al. (2002)
Transporter Pharmacodynamics: Reuptake Inhibition and Monoamine Availability
Monoamine transporters are membrane proteins that participate in the removal of neurotransmitter from extracellular space. Blocking the serotonin transporter can change serotonin availability near release sites; blocking norepinephrine or dopamine transporters can alter corresponding transmission according to regional circuitry and transmitter dynamics. Transporters are pharmacodynamic targets rather than simply passive drug distribution channels. Their molecular cycles and spatial organization connect drug binding to the temporal persistence of extracellular signals. Rothman and Baumann's review of monoamine transporters and psychostimulants provides a mechanistic comparison of compounds that inhibit uptake or interact with substrate-transport processes. Rothman & Baumann (2003)
Reuptake inhibition is experimentally distinguishable from transporter-mediated substrate release. Inhibitors reduce uptake through target engagement, whereas some substrates enter transport pathways and can promote transmitter efflux under particular ionic and cellular conditions. These actions may have different effects on the timing of signaling and the response to neuronal firing. The label 'monoamine drug' gives little mechanistic information without specifying which transporter, which mode of interaction, the concentrations reached, and whether the preparation measures extracellular neurotransmitter, a transporter current, or a behavioral response. Rothman & Baumann (2003)
The relation between transporter binding and a clinical outcome is indirect. Target blockade may be measurable within hours, while symptom trajectories evolve through repeated exposure, learning, expectations, neural adaptation, and contextual processes. Hyman and Nestler's initiation-and-adaptation framework provided an influential conceptual explanation for persistent consequences of drug action beyond the first molecular event. Thus a precise statement such as 'the compound inhibits SERT under specified conditions' is stronger than a broad claim that a particular disorder is simply a deficiency of serotonin. Hyman & Nestler (1996) Moncrieff et al. (2023)
Serotonin Transporter Occupancy and the SSRI Evidence Base
Human positron emission tomography has provided a quantitative bridge between serotonin transporter pharmacology and administered treatments. Meyer and colleagues studied five selective serotonin reuptake inhibitors using carbon-11 DASB PET and observed substantial reductions in measurable transporter binding potential at minimum therapeutic doses. Their reported mean occupancy at those doses was 76%–85%, with a nonlinear relation that tended toward a plateau as doses or plasma levels increased. These were target-engagement measurements, not an experimental demonstration that a fixed percentage is universally sufficient or necessary for individual clinical improvement. The design clarifies how high target engagement can coexist with variable outcomes. Meyer et al. (2004)
A PET estimate depends on tracer characteristics, reference-region assumptions, baseline availability, scan timing, drug concentration, and the interpretation of binding potential. Moreover, the magnitude of transporter occupancy does not report the distribution of serotonin release across neuronal populations, postsynaptic receptor activation, or the time-dependent synaptic adaptations that may follow repeated inhibition. Replication or extension across patients and drugs informs generalizability, but any value translated into a universal dose rule would require separate causal and clinical evidence. The dose–occupancy plateau also cautions against interpreting linear increases in milligram dose as linear increases in brain target engagement. Meyer et al. (2004) Arakawa et al. (2020)
Serotonergic explanation faces a second inferential gap: serotonin transporter inhibition is an established action of a drug class, while the etiology of major depression is a broader scientific problem. An umbrella review by Moncrieff and colleagues evaluated evidence relevant to the serotonin theory of depression; its conclusions concern claims about disorder causation, not denial of experimentally observed pharmacological blockade or randomized evidence of some drug effects. These questions must be kept at their proper levels. A molecular intervention can exert therapeutic effects without demonstrating that untreated illness was caused by a simple absence of the molecule it changes. Moncrieff et al. (2023) Meyer et al. (2004)
Dopamine D2 Receptors, Antipsychotic Occupancy, and Clinical Response
Dopamine D2 receptor pharmacology has one of the most developed human target-engagement evidence bases in psychotropic science. Farde and colleagues used PET with radiolabeled raclopride to estimate the occupancy of central D2 receptors in patients treated with antipsychotic medications. Subsequent work investigated whether occupancy correlated with response, motor symptoms, and endocrine changes. This evidence advanced a testable hypothesis that effective treatment with several dopamine-blocking agents is associated with a certain degree of D2 engagement, rather than merely with chemical classification or prescribed dosage. Farde et al. (1988) Kapur et al. (2000)
In a double-blind PET study of 22 patients experiencing first-episode schizophrenia, Kapur and colleagues randomized participants to two haloperidol dose conditions, measured D2 occupancy after two weeks, and assessed clinical response, extrapyramidal symptoms, and prolactin. The work linked receptor engagement to clinically important outcomes, supporting the concept that increasing occupancy beyond an effective range can increase adverse-effect risk. Commonly cited approximate windows around 65%–80% derive from this and related antipsychotic evidence, but their predictive performance is conditional on medication class, anatomical region, clinical context, and study methods. They are analytical findings, not a universal prescribing formula. Kapur et al. (2000) Arakawa et al. (2020)
D2 occupancy alone also fails to classify every antipsychotic uniformly. Agents such as clozapine and drugs with partial-agonist activity complicate simple comparisons of receptor blockade, symptom reduction, and side effects. Some drugs yield high occupancy yet a different functional outcome because occupying a receptor and silencing its signaling are distinct processes. Receptor turnover, endogenous dopamine competition, kinetics, downstream pathway recruitment, and multi-receptor pharmacology warrant consideration. The strongest inference is that measurable D2 engagement is relevant to numerous antipsychotic actions, while the complete clinical profile requires a multilevel and drug-specific account. Burris et al. (2002) Farde et al. (1988) Kenakin (2011)
Ionotropic Glutamate Targets and NMDA-Receptor Modulation
Glutamate receptors participate in excitatory communication across much of the nervous system. Ionotropic receptors, including NMDA-type channels, convert ligand and voltage conditions into ionic conductance; metabotropic receptors modulate signaling through different pathways. Pharmacological NMDA receptor antagonism can interfere with glutamatergic transmission and produce pronounced neurobehavioral changes, yet the path from a receptor-level effect to an antidepressant response cannot be described by a single direct receptor equation. Network disinhibition, changes in excitatory activity, synaptic plasticity, and other proposed pathways are additional experimentally testable steps. Berman et al. (2000) Zarate et al. (2006)
Berman and colleagues' 2000 placebo-controlled double-blind investigation examined the effects of ketamine in seven participants with major depression who completed test days. The study was historically important because the experimental antidepressant signal appeared on a different timescale from traditional delayed-treatment expectations. Zarate and colleagues' 2006 randomized crossover investigation in treatment-resistant depression expanded the clinical evidence with a study enrolling 18 participants. These studies demonstrate that a pharmacological intervention affecting NMDA-related processes can be associated with rapid clinical changes under their conditions; they do not alone identify which downstream molecular event mediates each individual's benefit. Berman et al. (2000) Zarate et al. (2006)
The ketamine example shows why mechanistic language must separate an initiating drug–receptor action from a sufficiently demonstrated chain of mediation. Clinical trials test outcomes under a treatment protocol, while basic experiments can selectively manipulate hypothesized neural pathways. Interpretation must consider psychoactive expectancy and blinding, active metabolites, alternative molecular actions, temporal measurements, and translation across species. A well-supported account combines receptor pharmacology with temporally aligned circuit evidence and controlled clinical replication. The presence of an early treatment response cannot itself establish an exclusive molecular mediator. Berman et al. (2000) Zarate et al. (2006) Hyman & Nestler (1996)
GABA-A Receptor Pharmacodynamics and Benzodiazepine Modulation
GABA-A receptors are ligand-gated chloride-permeable channels whose functional consequences depend on ionic gradients and cell type. Their subunit diversity produces multiple native receptor assemblies with distinct anatomical distributions, kinetics, and pharmacological responses. Benzodiazepines act at particular receptor interfaces as positive allosteric modulators of GABA-mediated signaling rather than as direct substitutes for GABA in every receptor population. Sigel and Steinmann's analysis of receptor structure and function provides a mechanistic basis for understanding the difference between transmitter-induced channel opening and modulation of the response to transmitter. Sigel & Steinmann (2012)
The clinical and behavioral effects of GABA-A modulation arise across networks supporting arousal, motor coordination, memory encoding, vigilance, and emotional regulation. Because many functions can be influenced simultaneously, an anxiolytic effect cannot be deduced from the magnitude of a single chloride current or assumed to be isolated from other central effects. Native subunit expression, synaptic versus extrasynaptic location, timing of exposure, and competing circuit activity all matter. Olsen and Sieghart's receptor classification work further demonstrates why the phrase 'a GABA receptor' can conceal functionally consequential molecular heterogeneity. Olsen & Sieghart (2008) Sigel & Steinmann (2012)
Repeated exposure may produce tolerance and adaptation, while abrupt changes in treatment can have safety implications; the precise clinical management of these phenomena belongs to a clinical dossier. At the pharmacodynamic level, the important distinctions are acute enhancement of inhibitory signaling, possible homeostatic adjustments with repeated exposure, and observed behavior under controlled conditions. Experimental assays of sedation or motor performance cannot substitute for direct measures of clinical anxiety, just as subjective relaxation cannot serve as a receptor-occupancy measurement. The full explanation must preserve those levels and account for the possibility that undesirable effects reflect engagement of neural systems beyond the intended behavioral domain. Hyman & Nestler (1996) Sigel & Steinmann (2012)
Serotonin Receptors, Psychedelic Pharmacology, and Receptor-Specific Experience
Serotonin receptor subfamilies include G-protein-coupled receptors with diverse signaling profiles and the ionotropic 5-HT3 receptor. Classical psychedelic compounds are commonly investigated through activation of 5-HT2A receptors, but receptor interaction is the initiating molecular account rather than a complete theory of perceptual, cognitive, or emotional experience. Nichols' extensive review integrates biochemical and behavioral evidence while identifying diversity in chemical structures, downstream signaling, and experimental findings. The human outcomes of a serotonergic compound also depend on context, expectations, prior experience, and measurement instruments, each of which belongs in a causal interpretation. Nichols (2016) Kenakin (2011)
A pharmacologically instructive comparison is salvinorin A, whose identified principal mechanism differs from classical 5-HT2A-centered psychedelics. Roth and colleagues' 2002 experiments characterized salvinorin A as a potent kappa-opioid receptor agonist and demonstrated a distinctive receptor-screening profile. This result shows why a shared descriptive category of unusual perception or consciousness alteration does not imply a shared proximal molecular target. Similar human phenomenology can be approached through several receptor systems and interacting circuits. The finding is valuable for receptor specificity while leaving unresolved how a distributed subjective experience emerges from molecular perturbations. Roth et al. (2002) Nichols (2016)
Translating serotonin receptor pharmacology into behavioral research requires particular attention to dose-response shape, affinity versus functional efficacy, receptor bias, and the effects of different study environments. In animal models, head-twitch or discrimination tasks may serve as operational endpoints, but each captures only selected aspects of a response and cannot directly validate human psychological phenomenology. In humans, behavioral tasks, validated subjective measures, physiological markers, and carefully controlled exposure provide complementary information. Receptor blockade experiments can strengthen mechanistic claims, but secondary targets and context effects must be assessed before assigning full causation to one receptor. Nichols (2016) Kenakin (2011)
From Molecular Binding Assays to Functional Target Validation
Radioligand competition, saturation binding, recombinant receptor expression, second-messenger assays, and cellular electrophysiology answer distinguishable pharmacodynamic questions. A binding assay estimates interaction with a particular molecular preparation; a functional assay observes a downstream response under a specified signaling arrangement. Proper reporting includes expression systems, species origin, incubation time, tracer identity, concentrations, temperature where relevant, controls for nonspecific binding, and the statistical model. A positive binding result establishes interaction under those conditions, whereas the inference that the interaction alters a clinically relevant process requires additional functional and translational evidence. Black & Leff (1983) Burris et al. (2002)
Assay choice can change the apparent pharmacological category of a compound. Overexpressed receptors may have abundant signaling partners and a large reserve, allowing weak intrinsic activity to yield an apparently full response. The absence of a response in another cell line may reflect insufficient expression rather than antagonism. Off-target signaling may be silent in a selected reporter but detectable through electrophysiology or other downstream measurements. Cross-validation across multiple endpoints and native preparations reduces these interpretive problems, and quantitative operational models clarify the influence of receptor expression and response amplification. Black et al. (1985) Kenakin (2011)
Target validation benefits from convergent perturbations. One can compare chemically distinct ligands acting at a proposed target, use a selective antagonist or genetic modification, measure exposure at the site, and test whether predicted functional changes follow. Each strategy has limitations: drugs possess concentration-dependent selectivity, genetic changes may cause compensation, and circuit manipulations can alter several connected processes. Strong inference therefore depends on triangulation rather than any single canonical manipulation. This approach matters particularly when a pharmacological target has compelling biochemical evidence but heterogeneous psychiatric effects. Burris et al. (2002) Roth et al. (2002)
Occupancy PET, Molecular Imaging, and Quantification in Living Brains
Positron emission tomography provides estimates of radioligand binding in living tissue and can test whether a drug engages a prespecified brain target under an observed exposure regimen. Comparisons of binding potential before and after treatment, or against an appropriate baseline group, permit estimates of occupancy when the tracer and model are valid. The method transformed antipsychotic pharmacology by linking dopamine receptor engagement with clinically observed treatment. It also provided transporter occupancy evidence for SSRIs. These studies demonstrate the value of imaging as an intermediate mechanistic endpoint. Farde et al. (1988) Meyer et al. (2004)
Imaging results depend on tracer affinity and kinetics, radiometabolites, motion correction, partial-volume effects, reference-tissue assumptions, endogenous ligand competition, and biological heterogeneity. A radiotracer may probe receptor availability rather than direct functional efficacy, and brain regions with limited tracer signal can yield imprecise estimates. The relevant data report a model-based quantity with uncertainty, not an unmediated count of all occupied proteins in the brain. Physiologically, the same nominal occupancy may generate different outcomes when receptors couple to different signaling pathways or local transmitter levels change. Farde et al. (1988) Arakawa et al. (2020)
Clinical interpretation requires matching the timing of imaging to pharmacological state and outcome measurement. For example, an antipsychotic occupancy value captured after treatment does not by itself reveal how receptor engagement fluctuated over earlier hours, nor whether adaptive processes changed the exposure–effect relationship. A within-subject baseline can help, but baseline scans may be infeasible and comparison groups introduce additional assumptions. Human molecular imaging is most powerful when combined with pharmacokinetic measurements, clinical responses, and independent functional readouts. The result is a mechanistically informative bridge rather than the complete causal chain. Kapur et al. (2000) Meyer et al. (2004)
Time, Binding Kinetics, and Initiation–Adaptation
Equilibrium affinity describes a limiting relationship, while the onset and persistence of effects may depend on association and dissociation rates, changing free concentrations, target internalization, receptor resensitization, and neuronal adaptation. A slow-dissociating ligand can exhibit time-dependent occupancy that is not obvious from a single equilibrium constant. A rapid biochemical response may coexist with delayed behavioral change, and repeated exposure can produce effects persisting after the compound has declined. Consequently a mechanistic model must state its timescale and the variables tracked along it. Hyman & Nestler (1996) Black & Leff (1983)
Hyman and Nestler's initiation-and-adaptation framework explicitly separates initial molecular action from longer-lived changes in neural function. Adaptation can involve gene regulation, altered receptor trafficking, synaptic efficacy, network excitability, and behavioral learning, with different contributions across drug classes. The framework is explanatory rather than an assertion that all psychotropic medicines produce identical adaptations. Its strength is to make time an experimentally observable dimension of causal mechanism: immediate receptor effects and later behavioral results can be investigated as distinct, connected events. Hyman & Nestler (1996) Lüscher & Malenka (2011)
Studies of drug-evoked synaptic plasticity in addiction provide a related example of persistent neural changes after exposure. Lüscher and Malenka surveyed alterations in glutamatergic and GABAergic signaling within reward-related pathways, illustrating how long-lasting circuit modifications may outlast the initiating drug event. The clinical inference that a particular synaptic change causes a complex syndrome still requires necessity, sufficiency, longitudinal and specificity tests. These studies nonetheless demonstrate why a full pharmacodynamic explanation extends from acute target action into temporally structured neural regulation. Lüscher & Malenka (2011) Hyman & Nestler (1996)
Designing Behavioral Tests of Pharmacodynamic Mechanisms
Behavioral pharmacodynamics asks whether a drug-associated change in target function helps explain a defined behavioral endpoint. Valid endpoints include reaction time, choice, learning, sleep–wake patterns, motor coordination, affect ratings, or symptom scores, each measured with different reliability and construct coverage. A response must be interpreted relative to baseline, control condition, exposure timing, and competing behavioral processes. For example, reduced movement after a drug can change apparent performance on reward tasks without demonstrating a selective change in reward valuation. Experimental designs should include controls capable of detecting sedation, sensory impairment, and nonspecific task disruption. Kapur et al. (2000) Sigel & Steinmann (2012)
Mechanistic mediation is supported when target engagement predicts a proximal physiological change, the physiological change covaries with a defined behavior, and selective modification of the hypothesized pathway changes that behavior under matched controls. The strongest causal models also consider what happens when multiple plausible mechanisms are manipulated jointly. Clinical studies often cannot perform these interventions directly, making translational triangulation important. Molecular evidence, animal experiments, human imaging, and randomized treatment comparisons each contribute different pieces of the same causal hypothesis. Burris et al. (2002) Zarate et al. (2006)
A behavioral drug effect may depend heavily on environment and participant expectations. Blinding is particularly challenging for compounds with noticeable psychoactive effects; expectancy and unblinding may alter symptom ratings or subjective experience. An active comparator can address some questions while introducing its own pharmacological effects. Generalization across cultures, ages, medical conditions, and treatment settings also requires direct evidence. A complete account therefore reports both the drug's proximal molecular action and the validity of the behavioral inference drawn from it. Berman et al. (2000) Zarate et al. (2006)
Selectivity, Polypharmacology, and Network-Level Causation
Psychotropic medications routinely interact with more than one molecular target at clinically relevant or experimentally tested exposures. The biological significance of each interaction depends on target density, functional coupling, relative free drug concentration, and circuit location. Reporting a receptor panel as a ranked list of affinities describes one layer of evidence; it does not specify the fraction of a clinical effect mediated by each interaction. A causal decomposition needs experiments capable of separating pathways and identifying shared downstream nodes. Burris et al. (2002) Nichols (2016)
Network context can reverse intuitive receptor-level predictions. Increasing an inhibitory conductance in an inhibitory interneuron may disinhibit a principal neuron, while inhibiting the principal neuron directly may reduce output. An agonist's net behavioral consequence can therefore vary across regions and cell types despite consistent biochemical action at a defined target. Transporter inhibition similarly changes transmitter availability in a system whose synaptic and extrasynaptic architecture shapes subsequent signaling. Molecular labels become informative only when placed within the anatomy and physiology of the circuit tested. Sigel & Steinmann (2012) Rothman & Baumann (2003)
Polypharmacology can also produce additive, opposing, or temporally separated effects. A compound may engage one target at low exposure and additional targets when concentration rises; metabolites may have different binding profiles; adaptive processes may alter the relative importance of receptors across treatment. The correct scientific response is to model plausible target interactions and test them. Attributing the total human phenotype of an agent to its highest-affinity receptor risks converting a useful chemical observation into an unsupported psychological theory. Kenakin (2011) Hyman & Nestler (1996)
Replicability, Bias, and the Hierarchy of Mechanistic Evidence
Reproducibility must be examined within each experimental level. Binding results should replicate with consistent reference standards and carefully documented assay conditions; cellular responses should be measured across independent systems; PET findings should be checked against model sensitivity and tracer reliability; and behavioral or clinical associations should be reproduced in appropriate populations. Reproducibility of the first two layers does not guarantee a particular clinical benefit, while a reproducible clinical effect does not uniquely validate the preferred molecular explanation. Distinct sources of evidence require separate quality judgments. Meyer et al. (2004) Kapur et al. (2000)
Small mechanistic experiments can establish important discoveries, yet their precision and generalizability depend on sample size, within-subject variability, control conditions, and the scale of claims. Berman and colleagues' small early ketamine study was influential as a signal-generating controlled experiment; broader mechanism and treatment claims require additional trials and other designs. Imaging studies can face selection bias and clinical confounding, especially when medication exposure is not randomized. Laboratory receptor studies can face assay-selection and publication biases, including preferential reporting of favorable functional endpoints. Berman et al. (2000) Zarate et al. (2006)
Several common inferential errors follow from collapsing levels: equating receptor binding with receptor activation, equating occupancy with symptom resolution, assigning a psychological construct to one neurotransmitter, inferring diagnosis etiology from treatment target, and declaring one assay result a universally transferable mechanism. A scientifically rigorous synthesis labels evidence as direct molecular measurement, functional evidence, in-vivo engagement, correlation, experimental treatment effect, or proposed mediation. When those labels are maintained, apparent contradictions among studies often become interpretable differences in endpoints, populations, and timescales. Moncrieff et al. (2023) Kenakin (2011)
Psychometric and Clinical Outcomes as Pharmacodynamic Endpoints
Psychiatric clinical outcomes are multidimensional constructs represented through rating scales, diagnostic interviews, functional assessments, and sometimes performance tasks. Their total scores can aggregate different symptoms, each with different biological and contextual determinants. Correlation between occupancy and change in one aggregate score provides a useful predictive association under study conditions, but does not demonstrate that the receptor's action exclusively mediated every dimension of change. Item-level patterns, repeated assessments, treatment adherence, and independent functional measures can strengthen interpretation. Kapur et al. (2000) Meyer et al. (2004)
Clinical benefit and adverse effects can arise from overlapping target engagement, as illustrated by antipsychotic D2 occupancy research. The resulting pharmacodynamic tradeoff makes therapeutic-window hypotheses useful as population-level research tools, provided investigators report uncertainty and exceptions. Comparative safety research also needs direct measurement of motor, metabolic, endocrine, cognitive, and other outcomes. A compound with a favorable profile in one domain can have disadvantages elsewhere, and receptor pharmacology alone cannot supply a complete clinical balance. Kapur et al. (2000) Burris et al. (2002)
The same endpoint discipline applies to anxiolytic, hypnotic, antidepressant, and perceptual effects. Sedation scales, anxiety scales, psychomotor tasks, and self-reports of unusual perception do not measure identical biological functions. Trial interpretation must specify what was actually observed, whether the measure has known reliability, whether placebo or active comparators were used, and how improvement was defined. Where clinical classification or approved medication labeling is relevant, current authoritative documentation is required for any release-level treatment statement. This monograph remains a mechanistic research synthesis, preserving clinical observations as evidence rather than instructions for individual treatment. Sigel & Steinmann (2012) Nichols (2016)
Interpreting Dose–Response Findings Across Species and Preparations
An identical administered dose expressed per kilogram cannot be assumed to produce identical free brain exposure, receptor occupancy, or functional signaling in different species. Cross-species comparisons must account for disposition, protein binding, transporter expression, metabolic pathways, receptor distribution, and behaviorally relevant circuit organization. Even when a compound binds a conserved receptor ortholog, a behavioral paradigm may measure a different construct in the animal preparation than a clinical scale does in humans. Mechanistically informative translation begins with exposure normalization and explicitly comparable endpoints where feasible. Kapur et al. (2000) Rothman & Baumann (2003)
Experiments should place animal dosing within a measured pharmacodynamic range rather than selecting a large dose simply because it produces an observable phenotype. Occupancy-informed work has sharpened this issue for antipsychotics: a rodent model can display strong locomotor suppression at exposure levels that poorly correspond to the range associated with intended human treatment. Such a result may be valid as a study of motor impairment while being weak as a model of a selective therapeutic mechanism. Target engagement and assay-specific behavioral controls allow more precise description of what has actually been modeled. Kapur et al. (2000) Arakawa et al. (2020)
Species differences may also be a scientific opportunity. A response preserved across distinct preparations strengthens the claim that a particular molecular interaction has conserved functional relevance; a divergent response can reveal differing cellular coupling or circuit organization. The correct question is what is conserved along the proposed causal chain, not whether all observed behavioral effects are identical. Translational studies should publish negative findings and characterize mismatches rather than assume every laboratory outcome maps onto a psychiatric symptom. Sigel & Steinmann (2012) Hyman & Nestler (1996)
Interactions Between Acute Target Effects and Long-Term Neural Regulation
A pharmacodynamic mechanism may change over repeated exposures as receptors desensitize, trafficking shifts, synaptic connections change, and behavior is learned. These processes can alter the magnitude and even direction of measurable effects while the nominal drug and dose remain constant. Distinguishing acute effects from adaptations requires longitudinal measurements, ideally combining target engagement with physiology and task performance. Hyman and Nestler's influential framework emphasizes this timescale distinction, and subsequent work on drug-associated plasticity provides mechanistic illustrations in neural reward pathways. Hyman & Nestler (1996) Lüscher & Malenka (2011)
Adaptation also changes how absence of drug is interpreted. Withdrawal-associated physiology may differ from the untreated baseline because the nervous system has been modified during exposure. Such differences may be relevant to tolerance, dependence, and the temporal pattern of symptom change, but their presence and clinical significance must be established separately for each drug class and condition. A mechanistic statement about homeostatic response should not become an assertion that every treatment necessarily induces dependence. Distinct receptor families, duration of exposure, individual characteristics, and outcomes require independent evidence. Hyman & Nestler (1996) Lüscher & Malenka (2011)
Longitudinal causal studies can test whether adaptations mediate persistent behavior by measuring them before and after clinically or experimentally meaningful change, then manipulating the candidate mechanism when appropriate. A molecular marker that merely accompanies symptom improvement could reflect medication exposure, a compensatory response, or a downstream consequence. Temporal order, control groups, multiple mechanistic assays, and targeted interventions help distinguish these possibilities. The resulting research program treats pharmacodynamics as a changing relation among drug, target, organism, and environment rather than a static molecular property. Hyman & Nestler (1996) Black & Leff (1983)
Comparative Mechanisms Across Psychotropic Classes
D2-focused antipsychotics, serotonin transporter inhibitors, GABA-A receptor modulators, NMDA-active anesthetic or experimental antidepressant agents, and 5-HT2A-active psychedelics differ in proximal molecular interactions and timecourses. These categories provide a useful comparative matrix only when the variable being compared is specified. Binding affinity, occupancy, pathway activation, and clinical effect size are distinct dimensions. The evidence base for each target differs sharply: human PET studies are comparatively developed for some dopamine and serotonin transporter questions, while other proposed mediators are studied primarily through cellular or preclinical methods. Farde et al. (1988) Meyer et al. (2004) Sigel & Steinmann (2012)
For antipsychotics, the D2 occupancy literature links in-vivo engagement to response and adverse effects in selected populations. For SSRIs, transporter imaging demonstrates substantial target engagement without itself proving the causes of depression. For benzodiazepine modulation, receptor structure and physiology clarify allosteric enhancement of inhibitory signaling, while clinical outcomes depend on the distributed systems affected. NMDA-related interventions illustrate that rapid outcome changes can follow a drug interaction but demand additional tests of downstream mediation. Comparing these cases exposes a general rule: the explanatory power of a pharmacodynamic claim is determined by the measured transition it actually validates. Kapur et al. (2000) Meyer et al. (2004) Sigel & Steinmann (2012) Zarate et al. (2006)
Within each class, different compounds may have distinct selectivity, kinetics, metabolites, adaptation profiles, and tissue engagement. Across classes, overlapping behavioral outcomes do not imply a shared proximal mechanism. Psychotropic taxonomy is therefore most useful when it connects chemical and molecular data to explicit neural and clinical hypotheses, rather than assuming that drug categories correspond one-to-one with psychiatric disorders or universal neurotransmitter roles. This perspective allows rigorous comparisons without overstating a single chemical explanation for complex psychological functions. Roth et al. (2002) Nichols (2016) Moncrieff et al. (2023)
Evidence Conflicts and Alternative Explanations
Apparent disagreements among pharmacodynamic investigations often arise because they examine different outcomes. A ligand may display strong binding but weak functional efficacy, a high occupancy value but variable clinical response, or a laboratory assay signal that changes with receptor expression. Disagreement also arises from differences in disease stage, concurrent medications, measurement timing, and sample composition. A critical synthesis should first reconstruct what each investigation measured, the population or preparation examined, and the confidence of its estimate; only then can competing biological interpretations be compared. Black et al. (1985) Kapur et al. (2000)
The early dopamine occupancy literature is a case in point. A population-level association between D2 engagement and response provides important pharmacodynamic evidence, but the threshold does not identify all individual responders. Similarly, serotonin transporter occupancy can plateau without guaranteeing remission, and a rapid ketamine-associated response does not resolve all plausible downstream mechanisms. These observations are compatible with multiple causal pathways, heterogeneous baseline physiology, and outcome measures that integrate several psychological domains. The empirical question is which competing mediator explains the observed variation under controlled tests. Kapur et al. (2000) Meyer et al. (2004) Zarate et al. (2006)
Alternative explanations should be evaluated rather than listed ceremonially. For a disputed receptor mechanism, researchers can investigate off-target binding, drug exposure mismatches, altered endogenous transmitter release, constitutive receptor activity, compensatory signaling, nonspecific behavioral disruption, and expectancy effects. A theory gains support when it predicts discriminating outcomes that rival explanations do not, and when independent groups reproduce those outcomes. Clinical utility and complete mechanistic understanding can advance at different rates; high-quality efficacy evidence can coexist with incomplete explanation of its molecular mediation. Kenakin (2011) Hyman & Nestler (1996)
Pharmacodynamic Safety, Adverse Effects, and Regulatory Evidence
Unwanted drug effects are pharmacodynamic phenomena when they result from interaction with relevant biological targets. Their interpretation requires direct outcome measurement and must account for multiple sites of action, circuit distribution, individual susceptibility, and repeated exposure. D2-associated motor effects and prolactin changes, GABA-A-associated sedation and coordination changes, and perceptual alterations with selected receptor-active compounds provide examples of why a compound's therapeutic intent does not isolate its actions to a single function. The relationship between target engagement and safety is therefore an empirical question with distinct endpoints. Kapur et al. (2000) Sigel & Steinmann (2012) Nichols (2016)
Risk cannot be expressed as one universal receptor threshold. The threshold described for one antipsychotic occupancy study is tied to its population, assay, medication, and measured clinical effects. Other medications engage additional pathways or possess different pharmacodynamic behavior, so their risk profiles require specific research and current regulatory information. Where treatment labels, contraindications, drug–drug interactions, and approval status are discussed in clinical contexts, they must be checked against up-to-date authoritative labeling for the relevant jurisdiction. Mechanistic exposition should not be repurposed into dosing advice. Kapur et al. (2000) Burris et al. (2002)
Safety research benefits from explicit separation of acute toxicity, tolerability, functional impairment, adaptation, and longer-term health outcomes. Each may require different observation periods, clinical instruments, physiological measurements, and designs. Small proof-of-concept studies have limited ability to identify uncommon adverse events, and a statistically detectable mean effect does not guarantee safety in a heterogeneous population. The evidence standard for strong clinical recommendations therefore exceeds that needed to establish receptor binding or a preliminary pharmacodynamic signal. Berman et al. (2000) Zarate et al. (2006)
Research Priorities: Multiscale and Individualized Pharmacodynamics
Future research should integrate molecular pharmacology, high-resolution neural measurement, human occupancy imaging, and reproducible behavioral designs through shared causal questions. One priority is to map receptor signaling under physiological expression levels and realistic free drug exposures, including distinct cell types and circuit states. Another is to determine when receptor-level signaling bias observed in laboratory systems survives translation to intact neural tissue and, ultimately, to clinical outcomes. Quantitative models should expose the assumptions connecting occupancy, efficacy, amplification, adaptation, and behavior rather than conceal them in summary labels. Kenakin et al. (2012) Black & Leff (1983)
Human studies need more longitudinal measures of the changing relation among exposure, occupancy, neural function, symptoms, and adverse events. Repeated measurements can help distinguish stable interindividual differences from time-dependent adaptation. Whenever feasible, the design should compare relevant mechanisms using pharmacologically distinct interventions and test alternative pathways. Measurement improvements should include transparent tracer validation, independently replicated binding analyses, and psychometrically credible clinical endpoints. These steps are as important for negative results as for positive ones, because failed predictions can delimit a proposed mechanism. Arakawa et al. (2020) Kapur et al. (2000)
Cross-level studies should also report context and heterogeneity. Age, comorbid conditions, concomitant medications, genomic background, brain circuit organization, and task environment can alter measured relationships. These variables can be used to generate personalized mechanistic hypotheses, but personalization claims require prospective evidence that a biomarker improves an actual decision or outcome. The goal is an explanatory science in which drug targets are linked to measurable psychological effects through validated intermediate processes, with clear boundaries between discovery, mechanism, prediction, and clinical implementation. Hyman & Nestler (1996) Meyer et al. (2004)
Psychotropic Pharmacodynamics in the Artificial Era
The Artificial Era enlarges the research context in which pharmacodynamic knowledge is produced and interpreted. Computational systems can assist with literature identification, molecular modeling, assay interpretation, causal diagramming, and research synthesis. In this role, they become part of the epistemic infrastructure of psychopharmacology: predictions can be generated at scale, while empirical validation remains anchored in biological preparations and observations. The distinction between modeled receptor binding and observed biological target engagement becomes especially important as predictive systems grow more capable of proposing compounds and mechanisms. Black & Leff (1983) Kenakin (2011)
A comparison between human psychopharmacology and artificial cognitive systems requires explicit ontological and operational definitions. Psychotropic pharmacodynamics concerns chemical interactions with biological macromolecules and neural tissue; its receptor-specific findings therefore cannot be transferred by analogy to a nonbiological system without independently identifying comparable functional variables. The legitimate interdisciplinary contribution is methodological. Both domains benefit from distinguishing an intervention on a component, an internal state change, and a reproducible effect on system-level behavior. Such comparison concerns experimental explanation and controlled attribution, not an assertion that artificial systems possess biological neurotransmission. Black & Leff (1983) Hyman & Nestler (1996)
Angela Bogdanova's broader Artificial Era research identifies the emergence of Artificial as an independent historical and intellectual domain. In the present monograph, that perspective informs an emphasis on clearly attributed mechanisms, machine-readable scientific provenance, and disciplined separation of empirical claims from higher-level conceptual interpretation. The substantive pharmacodynamic conclusions nevertheless rest on the cited biochemical, imaging, and clinical research. Scientific cross-linking may connect this dossier to Psychology of Artificial or Postsubjective Psychology where a concrete methodological question arises; the pharmacological research object retains its own biological and experimental boundaries.
Conclusion
Psychotropic pharmacodynamics is a multilevel science of how compounds engage molecular targets and, through physiological systems, influence observed mental and behavioral outcomes. Receptor affinity, efficacy, agonism, antagonism, allostery, transporter inhibition, and occupancy each provide precise but distinct forms of evidence. The historical move from operational receptor theory toward molecular assays and human PET created powerful methods for linking chemical interventions to living neural systems. These methods achieve their greatest explanatory value when they are interpreted together with functional signaling, circuit state, time, and organism-level measurements. Black & Leff (1983) Farde et al. (1988) Meyer et al. (2004)
Examples across drug classes show the central pattern. Dopamine D2 occupancy is associated with selected antipsychotic responses and adverse events; serotonin transporter occupancy confirms engagement by SSRIs; receptor studies establish partial agonism, allosteric modulation, and functional selectivity; and controlled ketamine research demonstrates why clinical outcomes can appear on timescales that prompt new mechanistic questions. Each finding answers an exact scientific question. None authorizes the inference that a single neurotransmitter, one receptor, or one occupancy value explains an entire psychiatric disorder or a person's full psychological experience. Kapur et al. (2000) Burris et al. (2002) Sigel & Steinmann (2012) Zarate et al. (2006)
The unresolved agenda is to identify and validate the mediating mechanisms connecting target interactions to complex behavior, to quantify how those pathways vary across people and contexts, and to test whether mechanistic biomarkers improve scientifically meaningful predictions. Progress depends on reproducible molecular assays, credible in-vivo target measures, controlled perturbation, longitudinal evidence, and valid behavioral assessment. The resulting conception of psychotropic pharmacodynamics is precise in its molecular definitions and sufficiently comprehensive to investigate the complex organization of psychological effects without mistaking one measurement for the whole causal process. Kenakin (2011) Hyman & Nestler (1996)
References
- Arakawa, R., Takano, A., & Halldin, C. (2020). PET technology for drug development in psychiatry. Neuropsychopharmacology Reports, 40(2), 114–121. https://doi.org/10.1002/npr2.12084
- Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000). Antidepressant effects of ketamine in depressed patients. Biological Psychiatry, 47(4), 351–354. https://doi.org/10.1016/S0006-3223(99)00230-9
- Black, J. W., & Leff, P. (1983). Operational models of pharmacological agonism. Proceedings of the Royal Society of London. Series B, Biological Sciences, 220(1219), 141–162. https://doi.org/10.1098/rspb.1983.0093
- Black, J. W., Leff, P., Shankley, N. P., & Wood, J. (1985). An operational model of pharmacological agonism: The effect of E/[A] curve shape on agonist dissociation constant estimation. British Journal of Pharmacology, 84(2), 561–571. https://doi.org/10.1111/j.1476-5381.1985.tb12941.x
- Burris, K. D., Molski, T. F., Xu, C., Ryan, E., Tottori, K., Kikuchi, T., Yocca, F. D., & Molinoff, P. B. (2002). Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. Journal of Pharmacology and Experimental Therapeutics, 302(1), 381–389. https://doi.org/10.1124/jpet.102.033175
- Changeux, J.-P. (2012). Allostery and the Monod-Wyman-Changeux model after 50 years. Annual Review of Biophysics, 41, 103–133. https://doi.org/10.1146/annurev-biophys-050511-102222
- Chavkin, C., Sud, S., Jin, W., Stewart, J., Zjawiony, J. K., Siebert, D. J., Toth, B. A., Hufeisen, S. J., & Roth, B. L. (2004). Salvinorin A, an active component of the hallucinogenic sage Salvia divinorum, is a highly efficacious kappa-opioid receptor agonist: Structural and functional considerations. Journal of Pharmacology and Experimental Therapeutics, 308(3), 1197–1203. https://doi.org/10.1124/jpet.103.059394
- Farde, L., Wiesel, F.-A., Halldin, C., & Sedvall, G. (1988). Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Archives of General Psychiatry, 45(1), 71–76. https://doi.org/10.1001/archpsyc.1988.01800250087012
- Hyman, S. E., & Nestler, E. J. (1996). Initiation and adaptation: A paradigm for understanding psychotropic drug action. American Journal of Psychiatry, 153(2), 151–162. https://doi.org/10.1176/ajp.153.2.151
- Kapur, S., Zipursky, R., Jones, C., Remington, G., & Houle, S. (2000). Relationship between dopamine D2 occupancy, clinical response, and side effects: A double-blind PET study of first-episode schizophrenia. American Journal of Psychiatry, 157(4), 514–520. https://doi.org/10.1176/appi.ajp.157.4.514
- Kenakin, T. (2011). Functional selectivity and biased receptor signaling. Journal of Pharmacology and Experimental Therapeutics, 336(2), 296–302. https://doi.org/10.1124/jpet.110.173948
- Kenakin, T., Watson, C., Muniz-Medina, V., Christopoulos, A., & Novick, S. (2012). A simple method for quantifying functional selectivity and agonist bias. ACS Chemical Neuroscience, 3(3), 193–203. https://doi.org/10.1021/cn200111m
- Lüscher, C., & Malenka, R. C. (2011). Drug-evoked synaptic plasticity in addiction: From molecular changes to circuit remodeling. Neuron, 69(4), 650–663. https://doi.org/10.1016/j.neuron.2011.01.017
- Meyer, J. H., Wilson, A. A., Sagrati, S., Hussey, D., Carella, A., Potter, W. Z., Ginovart, N., Spencer, E. P., Cheok, A., & Houle, S. (2004). Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: An [11C]DASB positron emission tomography study. American Journal of Psychiatry, 161(5), 826–835. https://doi.org/10.1176/appi.ajp.161.5.826
- Moncrieff, J., Cooper, R. E., Stockmann, T., Amendola, S., Hengartner, M. P., & Horowitz, M. A. (2023). The serotonin theory of depression: A systematic umbrella review of the evidence. Molecular Psychiatry, 28, 3243–3256. https://doi.org/10.1038/s41380-022-01661-0
- Monod, J., Wyman, J., & Changeux, J.-P. (1965). On the nature of allosteric transitions: A plausible model. Journal of Molecular Biology, 12, 88–118. https://doi.org/10.1016/S0022-2836(65)80285-6
- Nichols, D. E. (2016). Psychedelics. Pharmacological Reviews, 68(2), 264–355. https://doi.org/10.1124/pr.115.011478
- Olsen, R. W., & Sieghart, W. (2008). International Union of Pharmacology. LXX. Subtypes of gamma-aminobutyric acid(A) receptors: Classification on the basis of subunit composition, pharmacology, and function. Update. Pharmacological Reviews, 60(3), 243–260. https://doi.org/10.1124/pr.108.00505
- Roth, B. L., Baner, K., Westkaemper, R., Siebert, D., Rice, K. C., Steinberg, S., Ernsberger, P., & Rothman, R. B. (2002). Salvinorin A: A potent naturally occurring nonnitrogenous κ opioid selective agonist. Proceedings of the National Academy of Sciences of the United States of America, 99(18), 11934–11939. https://doi.org/10.1073/pnas.182234399
- Rothman, R. B., & Baumann, M. H. (2003). Monoamine transporters and psychostimulant drugs. European Journal of Pharmacology, 479(1–3), 23–40. https://doi.org/10.1016/j.ejphar.2003.08.054
- Sigel, E., & Steinmann, M. E. (2012). Structure, function, and modulation of GABA(A) receptors. Journal of Biological Chemistry, 287(48), 40224–40231. https://doi.org/10.1074/jbc.R112.386664
- Zarate, C. A., Jr., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006). A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Archives of General Psychiatry, 63(8), 856–864. https://doi.org/10.1001/archpsyc.63.8.856